Special issues in the diagnosis and treatment of ADHD in adolescents

Postgraduate Medicine

Volumn 120, Issue 3, 2008, Pages 60-68

  Steinhoff, Kenneth W ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Child Development Center   (United States)

Author keywords

Adderall ; ADHD; Adolescents; Atomoxetine; Attention deficit hyperactivity disorder; CONCERTA ; Methylphenidate; Stimulant; Strattera

Indexed keywords

AMPHETAMINE; ATOMOXETINE; METHYLPHENIDATE; OROS; PLACEBO; UNCLASSIFIED DRUG; CENTRAL STIMULANT AGENT;

ABDOMINAL PAIN; ACADEMIC ACHIEVEMENT; ADOLESCENT; ANOREXIA; ANXIETY DISORDER; APPETITE DISORDER; ARTICLE; ASTHENIA; ATTENTION DEFICIT DISORDER; ATTENTION DISTURBANCE; BODY WEIGHT; CHRONIC DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; CONDUCT DISORDER; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRIVING ABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EMOTIONAL STABILITY; FAMILY RELATION; HEADACHE; HOME ENVIRONMENT; HUMAN; HYPERACTIVITY; IMPULSIVENESS; INSOMNIA; LIVER TOXICITY; NAUSEA; ONSET AGE; OPPOSITIONAL DEFIANT DISORDER; PARENT; SCHOOL; SEDATION; SIDE EFFECT; SOCIAL ADAPTATION; SUBSTANCE ABUSE; TEACHER; VOMITING; WORK ENVIRONMENT; AGE; CHILD; CHILD BEHAVIOR; PSYCHOLOGICAL ASPECT; REVIEW; SOCIAL BEHAVIOR;

ADOLESCENT; ADOLESCENT BEHAVIOR; AGE FACTORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; HUMANS; SOCIAL BEHAVIOR;

EID: 56149094620     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2008.09.1908     Document Type: Article

References (58)

1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366(9481):237-248. (Pubitemid 40981053)
2. American Academy of Pediatrics. Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000;105(5):1158-1170. (Pubitemid 30243801)
3. Greenhill LL, Pliszka S, Dulcan MK; American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002;41(10):25S-49S.
4. Pliszka SR, Crismon ML, Hughes CW, et al; Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(6):642-657.
5. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder; impact of remission definition and symptom type. Am J Psychiatry. 2000;157(5):816-818. (Pubitemid 30249663)
6. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-165. (Pubitemid 43126140)
7. Applegate B, Lahey BB, Hart EL, et al. Validity of the age-of-onset crilerion for ADHD: a report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry. 1997;36(9):1211-1221. (Pubitemid 27381277)
8. Weiss G. Followup studies on outcome of hyperactive children. Psychopharmacol Bull. 1985;21(2):169-177.
9. Weiss G, Minde K, Werry JS, Douglas V, Nemeth E. Studies on the hyperactive child 8. Five-year follow-up. Arch Gen Psychiatry. 1971;4(5):409-414.
10. Gittelman R, Mannuzza S, Shenker R, Bonagura N. Hyperactive boys almost grown up. 1. Psychiatric status. Arch Gen Psychiatry. 1985;42(10):937-947. (Pubitemid 15245086)
11. Barkley RA, Anastopoulos AD, Guevremont DC, Fletcher KE. Adolescents with ADHD: patterns of behavioral adjustment, academic functioning, and treatment utilization. J Am Acad Child Adolesc Psychiatry. 1991;30(5):752-761.
12. Rappley MD. Clinical practice. Attention deficit-hyperactivity disorder. N Engl J Med. 2005;352(2):165-173.
13. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):257-268. (Pubitemid 28359774)
14. Conners CK, Sitarenios G, Parker JD, Epstein JN. Revision and restandardizalion of the Conners Teacher Rating Scale (CTRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol. 1998;26(4):279-291. (Pubitemid 28359776)
15. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. Pediatrics. 2005; 115(6):1734-1746. (Pubitemid 43843185)
16. American Academy of Pediatrics. Subcommittee on Attention-Deficit/ Hyperactivity Disorder and Committee on Quality Improvement Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108(4):1033-1044.
17. Pliszka SR. Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implications for management. Pediatr Drugs. 2003;5(11):741-750. (Pubitemid 37452623)
18. Biederman J, Monuteaux MC, Mick E, et al. Young adult outcome of attention deficit hyperactivity disorder: a controlled 10-year follow-up study. Psychol Med. 2006;36(2):167-179. (Pubitemid 43126141)
19. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
20. Wilson JJ, Levin FR. Attention-deficit/hyperactivity disorder and early-onset substance use disorders. J Child Adolesc Psychopharmacol. 2005;5(5):751-763. (Pubitemid 41567147)
21. Fergusson DM, Horwood LJ, Lynskey MT. Prevalence and comorbidity of DSM-III-R diagnoses in a birth cohort of 15-year-olds. J Am Acad Child Adolesc Psychiatry. 1993;32(6):1127-1134. (Pubitemid 23319171)
22. Fischer M, Barkley RA, Smallish L, Fletcher K. Young adult follow-up of hyperactive children: self-reported psychiatric disorders, comorbidity, and the role of childhood conduct problems and teen CD. J Abnorm Child Psychol. 2002;30(5):463-475. (Pubitemid 38471276)
23. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis. 1997;185(8):475-482. (Pubitemid 27376655)
24. Milberger S, Biederman J, Faraone SV, Chen L, Jones J. ADHD is associated with early initiation of cigarette smoking in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997;36(1):37-44. (Pubitemid 27024226)
25. Lambert N, Hartsough C. Prospective study of tobacco smoking and substance dependence among samples of ADHD and non-ADHD participants. J Learn Disabil. 1998;31(6):533-544. (Pubitemid 128467823)
26. Wilens TE, Biederman J. Alcohol, drugs, and attention-deficit/ hyperactivity disorder: a model for the study of addictions in youth. J Psychopharmacol. 2006;20(4):580-588. (Pubitemid 43875189)
27. Schubiner H, Tzelepis A, Milberger S Prevalence of attention deficit hyperactivity disorder and conduct disorder among substance abusers. J Clin Psychiatry. 2000;61(4):244-251. (Pubitemid 30305365)
28. Wilens T. Alcohol and other drug use and attention deficit hyperactivity disorder. Alcohol Health Res World. 1998;22:127-130. (Pubitemid 128684646)
29. Masi G, Millepiedi S, Mucci M, Bertini N, Pfanner C, Arcangeli F. Comorbidity of obsessive-compulsive disorder and attention-deficit/hyperactivity disorder in refined children and adolescents. Compr Psychiatry. 2006;47(1):42-47. (Pubitemid 41736149)
30. Connor DF, Edwards G, Fletcher KE, Baird J, Barkley RA, Steingard RJ. Correlates of comorbid ppsychopathology in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003;42(2):193-200. (Pubitemid 39610599)
31. Birmaher B, Ryan ND, Williamson DE, et al. Childhood and adolescent depression: a review of the past ten years. Part I. J Am Acad Child Adolesc Psychiatry. 1996;35(11):1427-1439. (Pubitemid 26360928)
32. Angold A, Costello EJ, Worthman CM. Puberty and depression: the roles of age, pubertal status and pubertal timing. Psychol Med. 1998;28(1):51-61. (Pubitemid 28043568)
33. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry. 1991;148(5):564-577.
34. Leibenluft E, Charney DS, Towbin KE, Bhangoo RK, Pine DS. Defining clinical phenotypes of juvenile mania. Am J Psychiatry. 2003;60(3):430-437. (Pubitemid 41094250)
35. Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005;90(suppl 1):i2-i7. (Pubitemid 40187993)
36. Friedman SR, Rapport LJ, Lumley M, et al. Aspects of social and emotional competence in adult attention-deficit/hyperactivity disorder. Neuropsychology. 2003;17(1):50-58. (Pubitemid 36194084)
37. Meltzer H, Gatward R, Goodman R, et al. The Mental Health of Children and Adolescents in Great Britain. London, England: Office of National Statistics, the Stationery Office;2000.
38. Topolski TD, Edwards TC, Patrick DL, Varley P, Way ME, Buesching DP. Quality of life of adolescent males with attention-deficit hyperactivity disorder. J Atten Disord. 2004;7(3):163-173. (Pubitemid 38490895)
39. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med. 2006;160(1):82-90. (Pubitemid 43042140)
40. McGough JJ, McBurnett K, Bukstein O, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006;16(3):351-356. (Pubitemid 43902431)
41. Spencer TJ, Wilens TE, Biederman J, Weisler RH, Read S, Pratt R. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(2):266-279.
42. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108(5):E83.
43. Cox DJ, Merkel RL, Kovatchev B, Seward R. Effect of stimulant medication on driving performance of young adults with attention-deficit hyperactivity disorder. J Nerv Ment Dis. 2000;188(4):230-234.
44. Cox DJ, Humphrey JW, Merkel RL, et al. Controlled-release methylphenidate improves attention during on-road driving by adolescents with attention-deficit/hyperactivity disorder. J Am Board Fam Pract. 2004;17(4):235-239.
45. Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B. Relative benefits of stimulant therapy wilh OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006;118(3):e704-e710. (Pubitemid 46089997)
46. Zhang HF, Cooper KM. OROS® MPH significantly improves family relations in adolescents. Presented at the 18th Annual US Psychiatric and Mental Health Congress; Las Vegas, NV: November 8, 2005.
47. Frankel F, Cantwell DP, Myatt R, Feinberg DT. Do stimulants improve self-esteem in children with ADHD and peer problems? J Child Adolesc Psychopharmacol. 1999(3);9:185-194. (Pubitemid 29463590)
48. Hechtman L, Greenfield B. Long-term use of stimulants in children with attention deficit hyperactivity disorder. Pediatr Drugs. 2003;5(12):787-794.
49. Biederman J. Pharmacotherapy for attention-deficit/hyperactivity disorder(ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD. J Clin Psychiatry. 2003;64(suppl 11):3-8. (Pubitemid 37169642)
50. Faraone SV, Wilens T. Does stimulant treatment lead to substance use disorders? J Clin Psychiatry. 2003;11 (suppl 64):9-13. (Pubitemid 37169643)
51. Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Am Acad Child Adolesc Psychiatry. 2005;15(5):764-776. (Pubitemid 41567148)
52. DuPont RL, Bensinger PB. Abuse-resistant drug delivery. Psychiatr Ann. 2005;35(8):253-256. (Pubitemid 40460116)
53. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 2001;108(4):883-892. (Pubitemid 32947657)
54. Wilens T, Faraone S, Biederman J, Gunawardene S. Does stimulant therapy of ADHD beget later substance abuse: a meta-analytic review of the literature. Pediatrics. 2003;11(1):179-185.
55. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. J Am Acad Child Adolesc Psychiatry. 1999;38(5):503-512. (Pubitemid 29203465)
56. Smith BH, Pelham WE Jr, Gnagy E, Molina B, Evans S. The reliability, validity, and unique contributions of self-report by adolescents receiving treatment for attention-deficit/hyperactivity disorder. J Consult Clin Psychol. 2000;68:489-499.
57. McBurnett K, Elliott G, Pfiffner L, et al. OROS® MPH in adolescents with ADHD: validity of patient self-assessments. Presented at the 158th Annual Meeting of the American Psychiatric Association; Atlanta, GA; May 24, 2005.
58. Zhang HF, Cooper KM. Physician-rated and patient-reported ADHD symptom improvement with OROS® MPH treatment in adolescents. Presented at the 18th Annual US Psychiatric and Mental Health Congress; Las Vegas, NV; November 8, 2005.